... We agree that crizotinib will still have a role in the treatment of patients with advanced ALK-rearranged NSCLC, however, probably only as a supplementary drug. In cell lines, crizotinib has been reported to be active in Ba/F3 cells harboring EML4-ALK resistance 1198F mutations or E1210K mutations... Finally, we agree with Urbanska et al. that comprehensive molecular profiling is also very important for treatment-naive patients, which may help identify potentially “detrimental” factors, such as TP53 mutations or BIM deletion polymorphisms.11,12 Nevertheless, a deeper understanding of the underlying biology mechanisms of acquired resistance to ALK inhibitors will help us further complement the therapeutic algorithm for patients with advanced ALK-rearranged NSCLC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2020.06.005
Authors: Fei Zhou, Caicun Zhou
